TransMedics Group, Inc. — Director's Dealing 2019

May 7, 2019

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: TransMedics Group, Inc. (TMDX)
CIK: 0001756262
Period of Report: 2019-05-06

Reporting Person: Provost Miriam (VP of US Regulatory & FDA Rel.)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2019-05-06	Stock Option (Right to Buy)	$0.92	J	100000	Disposed	2028-04-05	Common Stock (28571)	Direct
2019-05-06	Stock Option (Right to Buy)	$3.22	J	28571	Acquired	2028-04-05	Common Stock (28571)	Direct

Footnotes

F1: The option vested 25% on the first anniversary of the vesting commencement date, February 20, 2018, and at a rate of 2.0833% each month thereafter until the option is fully vested
on the fourth anniversary of the vesting date.

F2: The Stock Options reported herein as being disposed of are options to purchase common stock of TransMedics, Inc. Immediately prior to the closing of the Issuer's initial public
offering, pursuant to the terms of the Agreement and Plan of Merger and Reorganization by and among the Issuer, TransMedics, Inc. and TMDX, Inc., dated April 15, 2019 (the "Merger
Agreement"), each outstanding option to purchase shares of common stock of TransMedics, Inc. was converted into an outstanding option to purchase shares of common stock of the
Issuer adjusted on a 3.5-for-one basis, with a corresponding adjustment to the exercise price.